The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $1,140,600 were purchased by Treco Douglas A on Aug 06 ’25. At $57.03 per share, Treco Douglas A acquired 20,000 shares. The insider’s holdings grew to 22,000 shares worth approximately $1.26 million following the completion of this transaction.
Also, George Simeon purchased 989,812 shares, netting a total of over 51,499,918 in proceeds. Following the buying of shares at $52.03 each, the insider now holds 1,730,179 shares.
Before that, Patel Naimish had sold 3,932 shares from its account. In a trade valued at $141,316, the Chief Medical Officer traded CRISPR Therapeutics AG shares for $35.94 each. Upon closing the transaction, the insider’s holdings decreased to 3,932 shares, worth approximately $0.35 million.
As published in a research note from Evercore ISI on February 14, 2025, CRISPR Therapeutics AG [CRSP] has been rated up from an In-line to an Outperform and the price target has been revised to $99 from $60. Analysts at TD Cowen upgraded the stock from ‘”a Sell”‘ to ‘”a Hold”‘ outlook in a report released in mid February. As of February 03, 2025, H.C. Wainwright has initiated its “Buy” rating for CRSP. Earlier on August 06, 2024, Needham resumed its rating. Their recommendation was “a Buy” for CRSP stock.
Analyzing CRSP Stock Performance
On last trading session, CRISPR Therapeutics AG [NASDAQ: CRSP] rose 1.29% to $57.33. The stock’s lowest price that day was $57.0, but it reached a high of $60.825 in the same session. During the last five days, there has been a surge of approximately 1.76%. Over the course of the year, CRISPR Therapeutics AG shares have jumped approximately 21.95%. Shares of the company reached a 52-week high of $71.13 on 07/21/25 and a 52-week low of $30.04 on 04/07/25.
Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)
According to the 24-hour chart, there is a support level at 55.94, which, if violated, would cause prices to drop to 54.56. In the upper region, resistance lies at 59.77. The next price resistance is at 62.21. RSI (Relative Strength Index) is 52.15 on the 14-day chart, showing neutral technical sentiment.
Is CRISPR Therapeutics AG subject to short interest?
Stocks of CRISPR Therapeutics AG saw a sharp steep in short interest on 2025-07-31 dropping by -2.1 million shares to 23.45 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 25.54 million shares. A decline of -8.94% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.17 of the overall float, the days-to-cover ratio (short ratio) decline to 6.17.
Which companies own the most shares of CRISPR Therapeutics AG (CRSP)?
In terms of CRISPR Therapeutics AG share price expectations, FactSet research, analysts set an average price target of 84 in the next 12 months, up nearly 48.41% from the previous closing price of $56.6. Analysts anticipate CRISPR Therapeutics AG stock to reach 180 by 2025, with the lowest price target being 52. In spite of this, 8 analysts ranked CRISPR Therapeutics AG stock as Buy at the end of 2025. On August 02, 2024, Rodman & Renshaw assigned a price target of “a Buy” to the stock and initiated coverage with a $90.
